首页 > 最新文献

中华放射肿瘤学杂志最新文献

英文 中文
Study of the mechanism of anti-tumor effect of Metformin-enhanced radiotherapy in CT26WT cell lines or mouse models with transplanted tumors 二甲双胍增强放疗对CT26WT细胞系或移植瘤小鼠模型抗肿瘤作用机制的研究
Pub Date : 2020-03-15 DOI: 10.3760/CMA.J.ISSN.1004-4221.2020.03.010
X. Dai, Leilei Tao, Tingting Fang, Ping Chen, Haijun Sun, Zhifeng Wu, Xichun Dai
Objective To investigate the inhibitory effect and mechanism of Metformin (Met) combined with irradiation in CT26WT cell lines or mouse models with transplanted tumors. Methods CT26WT cell line was treated with 0.5μmol/L, 1.0μmol/L, 5.0μmol/L and 10.0μmol/L Met, and CellTiter Glo kit was used to detect the inhibitory effect of Met at different concentrations on the viability of CT26WT cells. CT26WT cell line was treated with the control, Met (10μmol/L), 15Gy irradiation and 15Gy irradiation+ Met (10μmol/L). Clone formation assay was employed to detect the cell proliferation activity. Bablc mouse models of transplanted tumors (tumor size>150 mm3) were established and randomly divided into the control, 15Gy irradiation, Met and 15Gy irradiation+ Met groups. Mice were given with 750 mg/kg Met at 24 h before irradiation. Transplanted tumor volume was measured regularly to delineate the growth curve of transplanted tumors and survival curve. The expression levels of P-H2AX and Sting proteins in CT26WT cells and transplanted tumors were detected by Western blot. The infiltration of CD8a (+ ) T cells in transplanted tumor tissues was detected by immunohistochemistry. Results The relative cell survival rate was 100%, 87.9%, 87.8%, 87.3% and 76.5% in the 0, 0.5, 1.0, 5.0 and 10.0μmol/L Met groups, respectively (all P<0.05). The inhibitory effect of 10.0μmol/L was significantly stronger than that of 5.0μmol/L (P<0.001). The colone formation rate 34.0%, 24.0%, 22.3% and 14.0% in the control, Met, 15Gy irradiation, Met+ 15Gy irradiation groups, respectively (all P<0.001). Western blot showed that compared with the control group, the expression of Sting protein was increased by 2.99-fold after Met treatment (P<0.001), and increased by 1.37-fold and 4.41-fold in the 15Gy irradiation and 15Gy irradiation+ Met groups (both P<0.01). Compared with the 15Gy irradiation group, the expression of P-H2AX protein was significantly increased by 1.43 times after treatment with 15Gy+ Met (P<0.001). The transplanted tumor growth curve showed that the transplanted tumor growth in the 15Gy+ Met group was slower than that in the control group[(1007.0±388.5) mm3vs. (2639.0±242.9) mm3, P<0.05)]. The overall survival time in the 15Gy irradiation+ Met group was 48 d, significantly longer than 32 d in the control group (P<0.001). Compared with the control group, the expression of P-H2AX and Sting proteins in the 15Gy+ Met group was increased by 8.8-fold and 1.6-fold (both P<0.001). Immunohistochemical staining showed that the infiltration of CD8a (+ ) T cells in the 15Gy irradiation+ Met group was significantly higher than that in the control group (P<0.01). Conclusions Met combined with radiotherapy can inhibit the proliferation and clone formation of colon cancer cells, probably by aggravating DNA damage and activating the Sting signaling pathway, eventually leading to the increase of CD8a (+ ) T cells in tumor tissues and enhancing the killing effect upon tran
目的探讨二甲双胍(Met)联合放疗对CT26WT细胞株或移植瘤小鼠模型的抑制作用及其机制。方法分别用0.5μmol/L、1.0μmol/L、5.0μmol/L和10.0μmol/L的Met处理CT26WT细胞,用CellTiter-Glo试剂盒检测不同浓度Met对CT26WT生存能力的抑制作用。用对照组、Met(10μmol/L)、15Gy照射和15Gy+Met(10%μmol/L)处理CT26WT细胞。采用克隆形成法检测细胞增殖活性。建立移植肿瘤(肿瘤大小>150mm3)的Bablc小鼠模型,并随机分为对照组、15Gy照射组、Met组和15Gy辐照+Met组。在照射前24小时给予小鼠750mg/kg Met。定期测量移植瘤体积,绘制移植瘤生长曲线和生存曲线。Western blot检测P-H2AX和Sting蛋白在CT26WT细胞和移植瘤中的表达水平。免疫组化检测CD8a(+)T细胞在移植瘤组织中的浸润。结果0、0.5、1.0、5.0和10.0μmol/L Met组的相对细胞存活率分别为100%、87.9%、87.8%、87.3%和76.5%(均P<0.05)。10.0μmol/L的抑制作用明显强于5.0μmol/L(P<0.001)。对照组、Met、15Gy、Met+15Gy组的结肠形成率分别为34.0%、24.0%、22.3%和14.0%,Western blot显示,与对照组相比,Met处理后Sting蛋白的表达增加了2.99倍(P<0.001),15Gy和15Gy+Met组分别增加了1.37倍和4.41倍(均P<0.01),移植瘤生长曲线显示,15Gy+Met组移植瘤生长缓慢[(1007.0±388.5)mm3 vs(2639.0±242.9)mm3,P<0.05)],与对照组相比,P-H2AX和Sting蛋白在15Gy+Met组的表达分别增加了8.8倍和1.6倍(均P<0.001)。免疫组化染色显示,15Gy+Met组CD8a(+)T细胞浸润明显高于对照组(P<0.01)癌症细胞的杀伤作用,可能是通过加重DNA损伤和激活Sting信号通路,最终导致肿瘤组织中CD8a(+)T细胞的增加,并增强对移植肿瘤细胞的杀伤效果。关键词:二甲双胍;Sting基因;H2AX基因;CT26WT细胞系;移植瘤/Bablc小鼠
{"title":"Study of the mechanism of anti-tumor effect of Metformin-enhanced radiotherapy in CT26WT cell lines or mouse models with transplanted tumors","authors":"X. Dai, Leilei Tao, Tingting Fang, Ping Chen, Haijun Sun, Zhifeng Wu, Xichun Dai","doi":"10.3760/CMA.J.ISSN.1004-4221.2020.03.010","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1004-4221.2020.03.010","url":null,"abstract":"Objective \u0000To investigate the inhibitory effect and mechanism of Metformin (Met) combined with irradiation in CT26WT cell lines or mouse models with transplanted tumors. \u0000 \u0000 \u0000Methods \u0000CT26WT cell line was treated with 0.5μmol/L, 1.0μmol/L, 5.0μmol/L and 10.0μmol/L Met, and CellTiter Glo kit was used to detect the inhibitory effect of Met at different concentrations on the viability of CT26WT cells. CT26WT cell line was treated with the control, Met (10μmol/L), 15Gy irradiation and 15Gy irradiation+ Met (10μmol/L). Clone formation assay was employed to detect the cell proliferation activity. Bablc mouse models of transplanted tumors (tumor size>150 mm3) were established and randomly divided into the control, 15Gy irradiation, Met and 15Gy irradiation+ Met groups. Mice were given with 750 mg/kg Met at 24 h before irradiation. Transplanted tumor volume was measured regularly to delineate the growth curve of transplanted tumors and survival curve. The expression levels of P-H2AX and Sting proteins in CT26WT cells and transplanted tumors were detected by Western blot. The infiltration of CD8a (+ ) T cells in transplanted tumor tissues was detected by immunohistochemistry. \u0000 \u0000 \u0000Results \u0000The relative cell survival rate was 100%, 87.9%, 87.8%, 87.3% and 76.5% in the 0, 0.5, 1.0, 5.0 and 10.0μmol/L Met groups, respectively (all P<0.05). The inhibitory effect of 10.0μmol/L was significantly stronger than that of 5.0μmol/L (P<0.001). The colone formation rate 34.0%, 24.0%, 22.3% and 14.0% in the control, Met, 15Gy irradiation, Met+ 15Gy irradiation groups, respectively (all P<0.001). Western blot showed that compared with the control group, the expression of Sting protein was increased by 2.99-fold after Met treatment (P<0.001), and increased by 1.37-fold and 4.41-fold in the 15Gy irradiation and 15Gy irradiation+ Met groups (both P<0.01). Compared with the 15Gy irradiation group, the expression of P-H2AX protein was significantly increased by 1.43 times after treatment with 15Gy+ Met (P<0.001). The transplanted tumor growth curve showed that the transplanted tumor growth in the 15Gy+ Met group was slower than that in the control group[(1007.0±388.5) mm3vs. (2639.0±242.9) mm3, P<0.05)]. The overall survival time in the 15Gy irradiation+ Met group was 48 d, significantly longer than 32 d in the control group (P<0.001). Compared with the control group, the expression of P-H2AX and Sting proteins in the 15Gy+ Met group was increased by 8.8-fold and 1.6-fold (both P<0.001). Immunohistochemical staining showed that the infiltration of CD8a (+ ) T cells in the 15Gy irradiation+ Met group was significantly higher than that in the control group (P<0.01). \u0000 \u0000 \u0000Conclusions \u0000Met combined with radiotherapy can inhibit the proliferation and clone formation of colon cancer cells, probably by aggravating DNA damage and activating the Sting signaling pathway, eventually leading to the increase of CD8a (+ ) T cells in tumor tissues and enhancing the killing effect upon tran","PeriodicalId":10288,"journal":{"name":"Chinese Journal of Radiation Oncology","volume":"29 1","pages":"203-206"},"PeriodicalIF":0.0,"publicationDate":"2020-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48143154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical comparison between ductal carcinoma in situ and ductal carcinoma in situ with microinvasion 导管原位癌与导管原位癌伴微侵的临床比较
Pub Date : 2020-03-15 DOI: 10.3760/CMA.J.ISSN.1004-4221.2020.03.007
Weixin Liu, Shulian Wang, Yu Tang, H. Jing, Jianyang Wang, Jiang-hu Zhang, J. Jin, Yong-wen Song, Weihu Wang, Yueping Liu, H. Fang, H. Ren, S. Qi, N. Lu, Yuan Tang, Ning Li, Yexiong Li
Objective To analyze the differences in the treatment patterns, clinical characteristics, treatment outcomes and prognostic factors between breast cancer patients with ductal carcinoma in situ (DCIS) and ductal carcinoma in situ with microinvasion (DCIS-MI). Methods Clinical data of 866 female patients including 631 DCIS cases and 235 DCIS-MI cases treated in our institution between 1999 and 2013 were retrospectively analyzed. The local control (LC), disease-free survival (DFS) and overall survival (OS) rates were calculated by Kaplan-Meier survival analysis. The prognostic factors were identified by Log-rank test. Results Similar LC, DFS and OS rates were obtained between two groups (all P>0.05). The univariate analysis demonstrated that Her-2-positive patients had worse OS and DFS than Her-2-negative counterparts. Patients undergoing breast-conserving surgery without radiotherapy had lower LC and DFS rates compared with those receiving radical mastectomy. Conclusions DCIS and DCIS-MI patients have similar clinical prognosis in terms of OS, LC and DFS. Her-2 positive is an unfavorable prognostic factor for DFS and OS. The LC and DFS rates in the breast-conserving surgery alone group are worse than those in the mastectomy group. Key words: Breast ductal carcinoma in situ; Breast ductal carcinoma in situ with microinvasion; Breast neoplasm/radiotherapy; Breast neoplasm/surgery; Prognosis
目的分析癌症导管原位癌(DCIS)与微浸润导管原位癌的治疗模式、临床特点、治疗结果及预后因素的差异。方法回顾性分析我院1999~2013年收治的866例女性患者的临床资料,其中DCIS 631例,DCIS-MI 235例。通过Kaplan-Meier生存分析计算局部对照(LC)、无病生存率(DFS)和总生存率(OS)。预后因素采用对数秩检验。结果两组患者的LC、DFS和OS发生率相似(均P>0.05)。单因素分析表明,Her-2阳性患者的OS和DFS比Her-2阴性患者差。与接受根治性乳房切除术的患者相比,在不接受放疗的情况下接受保乳手术的患者LC和DFS发生率较低。结论DCIS和DCIS-MI患者OS、LC和DFS的临床预后相似。Her-2阳性是DFS和OS的不利预后因素。单纯保乳手术组的LC和DFS发生率低于乳房切除术组。关键词:乳腺导管原位癌;乳腺导管原位癌伴微浸润;乳腺肿瘤/放射治疗;乳腺肿瘤/手术;预后
{"title":"Clinical comparison between ductal carcinoma in situ and ductal carcinoma in situ with microinvasion","authors":"Weixin Liu, Shulian Wang, Yu Tang, H. Jing, Jianyang Wang, Jiang-hu Zhang, J. Jin, Yong-wen Song, Weihu Wang, Yueping Liu, H. Fang, H. Ren, S. Qi, N. Lu, Yuan Tang, Ning Li, Yexiong Li","doi":"10.3760/CMA.J.ISSN.1004-4221.2020.03.007","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1004-4221.2020.03.007","url":null,"abstract":"Objective \u0000To analyze the differences in the treatment patterns, clinical characteristics, treatment outcomes and prognostic factors between breast cancer patients with ductal carcinoma in situ (DCIS) and ductal carcinoma in situ with microinvasion (DCIS-MI). \u0000 \u0000 \u0000Methods \u0000Clinical data of 866 female patients including 631 DCIS cases and 235 DCIS-MI cases treated in our institution between 1999 and 2013 were retrospectively analyzed. The local control (LC), disease-free survival (DFS) and overall survival (OS) rates were calculated by Kaplan-Meier survival analysis. The prognostic factors were identified by Log-rank test. \u0000 \u0000 \u0000Results \u0000Similar LC, DFS and OS rates were obtained between two groups (all P>0.05). The univariate analysis demonstrated that Her-2-positive patients had worse OS and DFS than Her-2-negative counterparts. Patients undergoing breast-conserving surgery without radiotherapy had lower LC and DFS rates compared with those receiving radical mastectomy. \u0000 \u0000 \u0000Conclusions \u0000DCIS and DCIS-MI patients have similar clinical prognosis in terms of OS, LC and DFS. Her-2 positive is an unfavorable prognostic factor for DFS and OS. The LC and DFS rates in the breast-conserving surgery alone group are worse than those in the mastectomy group. \u0000 \u0000 \u0000Key words: \u0000Breast ductal carcinoma in situ; Breast ductal carcinoma in situ with microinvasion; Breast neoplasm/radiotherapy; Breast neoplasm/surgery; Prognosis","PeriodicalId":10288,"journal":{"name":"Chinese Journal of Radiation Oncology","volume":"29 1","pages":"187-192"},"PeriodicalIF":0.0,"publicationDate":"2020-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46439156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of microRNA in predictingclinical efficacy of neoadjuvant chemoradiotherapy for rectal cancer microRNA在预测直肠癌新辅助放化疗临床疗效中的作用
Pub Date : 2020-03-15 DOI: 10.3760/CMA.J.ISSN.1004-4221.2020.03.016
Wenyan Yao, Q. Peng, Yaqun Zhu, Ye Tian
Neoadjuvant chemoradiotherapy (NCRT) has become the standard treatment for patients with locally advanced rectal cancer (LARC). However, the response to NCRT varies among LARC patients and a subset of patients show resistance to NCRT. NCRT may delay the timing of surgery and even reduce the overall survival. Therefore, it is of significance to identify biomarkers for predicting the clinical efficacy of NCRT, screen patients who are resistant to NCRT and perform surgery as early as possible, eventually establishing an individualized therapeutic strategy. MicroRNAs are a class of small non-coding RNAs that post-transcriptionally regulate gene expression, which areinvolved in multiple signaling pathways and DNA damage repair process and affect the radiosensitivity of rectal cancer cells. Many recent studies have evaluated the role of microRNA in predicting the response to NCRT. The purpose of this article is to review the research progress and validate the role of microRNA in predicting the clinical efficacy of NCRT for rectal cancer. Key words: Rectal neoplasm/neoadjuvant chemoradiotherapy; MicroRNA; Predict
新辅助放化疗(NCRT)已成为局部晚期直肠癌(LARC)患者的标准治疗方法。然而,LARC患者对NCRT的反应各不相同,一部分患者对NCRT有耐药性。NCRT可能会延迟手术时间,甚至降低总生存率。因此,鉴别生物标志物对预测NCRT临床疗效,筛选耐药患者并尽早进行手术治疗,最终制定个体化治疗策略具有重要意义。MicroRNAs是一类转录后调控基因表达的小分子非编码rna,参与多种信号通路和DNA损伤修复过程,影响直肠癌细胞的放射敏感性。最近的许多研究已经评估了microRNA在预测NCRT疗效中的作用。本文旨在综述相关研究进展,验证microRNA在预测直肠癌NCRT临床疗效中的作用。关键词:直肠肿瘤/新辅助放化疗;微rna;预测
{"title":"Role of microRNA in predictingclinical efficacy of neoadjuvant chemoradiotherapy for rectal cancer","authors":"Wenyan Yao, Q. Peng, Yaqun Zhu, Ye Tian","doi":"10.3760/CMA.J.ISSN.1004-4221.2020.03.016","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1004-4221.2020.03.016","url":null,"abstract":"Neoadjuvant chemoradiotherapy (NCRT) has become the standard treatment for patients with locally advanced rectal cancer (LARC). However, the response to NCRT varies among LARC patients and a subset of patients show resistance to NCRT. NCRT may delay the timing of surgery and even reduce the overall survival. Therefore, it is of significance to identify biomarkers for predicting the clinical efficacy of NCRT, screen patients who are resistant to NCRT and perform surgery as early as possible, eventually establishing an individualized therapeutic strategy. MicroRNAs are a class of small non-coding RNAs that post-transcriptionally regulate gene expression, which areinvolved in multiple signaling pathways and DNA damage repair process and affect the radiosensitivity of rectal cancer cells. Many recent studies have evaluated the role of microRNA in predicting the response to NCRT. The purpose of this article is to review the research progress and validate the role of microRNA in predicting the clinical efficacy of NCRT for rectal cancer. \u0000 \u0000Key words: \u0000Rectal neoplasm/neoadjuvant chemoradiotherapy; MicroRNA; Predict","PeriodicalId":10288,"journal":{"name":"Chinese Journal of Radiation Oncology","volume":"29 1","pages":"229-232"},"PeriodicalIF":0.0,"publicationDate":"2020-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41317181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Research progress on biomarkers for radiation-induced intestinal injury based on intestinal flora 基于肠道菌群的辐射肠损伤生物标志物研究进展
Pub Date : 2020-03-15 DOI: 10.3760/CMA.J.ISSN.1004-4221.2020.03.018
Junjun Zhang, S. Cai, Yongqiang Yang, Junyan Li, Ye Tian
Recently, the relationship between intestinal flora and its metabolites and tumorigenesis, inflammatory bowel diseasesas well as radiation-induced intestinal injury has captivated widespread attention from researchers. Accumulated evidence derived from nuclear accident investigation, animal model experiment and clinical research has proven the role of intestinal flora and its metabolites as the biomarkers to evaluate the radiation dose and severity of radiation-induced intestinal injury. This article reviews the relationship between intestinal flora and its metabolites and radiation-induced intestinal injury, aiming to provide theoretical reference for assessing the risk of radiation-induced intestinal injury. Key words: Intestinal flora; Metabolite; Radiation-induced injury; Biomarker
近年来,肠道菌群及其代谢产物与肿瘤发生、炎症性肠病以及放射性肠道损伤之间的关系引起了研究人员的广泛关注。从核事故调查、动物模型实验和临床研究中积累的证据已经证明,肠道菌群及其代谢产物作为评估辐射剂量和放射性肠损伤严重程度的生物标志物的作用。本文综述了肠道菌群及其代谢产物与放射性肠损伤的关系,旨在为评估放射性肠损伤风险提供理论参考。关键词:肠道菌群;代谢物;辐射损伤;生物标志物
{"title":"Research progress on biomarkers for radiation-induced intestinal injury based on intestinal flora","authors":"Junjun Zhang, S. Cai, Yongqiang Yang, Junyan Li, Ye Tian","doi":"10.3760/CMA.J.ISSN.1004-4221.2020.03.018","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1004-4221.2020.03.018","url":null,"abstract":"Recently, the relationship between intestinal flora and its metabolites and tumorigenesis, inflammatory bowel diseasesas well as radiation-induced intestinal injury has captivated widespread attention from researchers. Accumulated evidence derived from nuclear accident investigation, animal model experiment and clinical research has proven the role of intestinal flora and its metabolites as the biomarkers to evaluate the radiation dose and severity of radiation-induced intestinal injury. This article reviews the relationship between intestinal flora and its metabolites and radiation-induced intestinal injury, aiming to provide theoretical reference for assessing the risk of radiation-induced intestinal injury. \u0000 \u0000Key words: \u0000Intestinal flora; Metabolite; Radiation-induced injury; Biomarker","PeriodicalId":10288,"journal":{"name":"Chinese Journal of Radiation Oncology","volume":"29 1","pages":"237-240"},"PeriodicalIF":0.0,"publicationDate":"2020-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47561404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dose-escalation trial of lobaplatin weekly plus concurrent radiotherapy for local-regionally advanced nasopharyngeal carcinoma 洛铂联合放疗治疗局部-区域晚期鼻咽癌的剂量递增试验
Pub Date : 2020-03-15 DOI: 10.3760/CMA.J.ISSN.1004-4221.2020.03.003
X. Pang, D. Qing, Bin Zhao, D. Ma
Objective To define the maximum-tolerated dose (MTD) of lobaplatin (LBP) in a weekly regimen combined with concurrent radiotherapy in the treatment of locally advanced nasopharyngeal carcinoma (NPC). Methods A total of 18 cases with stage Ⅲ/IV A NPC were enrolled. Concurrent chemoradiotherapy was given to all the patients with a dose escalation of LBP. The initial dose of LBP was 15 mg/m2 with an escalating dose of 5 mg/m2. At least 3 patients were assigned into each group. Patients were proceeded into the next dose group if no dose-limiting toxicity (DLT) occurred until the MTD was achieved. Efficacy and toxicity were evaluated regularly. Results Three patients were assigned into the 10 mg/m2, 3 into the 15 mg/m2, and 6 into the 20 mg/m2 and 25 mg/m2 groups, respectively. Two patients experienced DLT in the 25 mg/m2 group. Hence, the MTD was determined as 20 mg/m2. At 3 months after corresponding treatment, the remission rate of nasopharyngeal tumors and neck-positive lymph nodes of the patients was 100%. The most common toxicity was reversible bone marrow suppression. Conclusions The MTD of weekly lobaplatin plus concurrent IMRT is 20 mg/m2 for locally advanced NPC. This regimen is reliable and safe, which is worthy of further clinical study. Key words: Nasopharyngeal neoplasm/concurrent chemoradiotherapy; Lobaplatin; Dose-limiting toxicity; Maximum tolerated dose
目的探讨洛铂联合放射治疗局部晚期鼻咽癌(NPC)的最大耐受剂量(MTD)。方法选取18例Ⅲ/IV期鼻咽癌患者。所有LBP剂量增加的患者均给予同步放化疗。LBP的初始剂量为15mg /m2,逐渐增加至5mg /m2。每组至少3例。如果在达到MTD之前没有发生剂量限制性毒性(DLT),则患者进入下一剂量组。定期评价疗效和毒性。结果10 mg/m2组3例,15 mg/m2组3例,20 mg/m2组和25 mg/m2组6例。25 mg/m2组2例患者出现DLT。因此,测定MTD为20 mg/m2。相应治疗3个月后,患者鼻咽肿瘤及颈阳性淋巴结的缓解率为100%。最常见的毒性是可逆的骨髓抑制。结论局部晚期鼻咽癌患者每周洛铂联合IMRT的MTD为20 mg/m2。该方案可靠、安全,值得进一步临床研究。关键词:鼻咽肿瘤/同步放化疗;Lobaplatin;Dose-limiting毒性;最大耐受剂量
{"title":"Dose-escalation trial of lobaplatin weekly plus concurrent radiotherapy for local-regionally advanced nasopharyngeal carcinoma","authors":"X. Pang, D. Qing, Bin Zhao, D. Ma","doi":"10.3760/CMA.J.ISSN.1004-4221.2020.03.003","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1004-4221.2020.03.003","url":null,"abstract":"Objective \u0000To define the maximum-tolerated dose (MTD) of lobaplatin (LBP) in a weekly regimen combined with concurrent radiotherapy in the treatment of locally advanced nasopharyngeal carcinoma (NPC). \u0000 \u0000 \u0000Methods \u0000A total of 18 cases with stage Ⅲ/IV A NPC were enrolled. Concurrent chemoradiotherapy was given to all the patients with a dose escalation of LBP. The initial dose of LBP was 15 mg/m2 with an escalating dose of 5 mg/m2. At least 3 patients were assigned into each group. Patients were proceeded into the next dose group if no dose-limiting toxicity (DLT) occurred until the MTD was achieved. Efficacy and toxicity were evaluated regularly. \u0000 \u0000 \u0000Results \u0000Three patients were assigned into the 10 mg/m2, 3 into the 15 mg/m2, and 6 into the 20 mg/m2 and 25 mg/m2 groups, respectively. Two patients experienced DLT in the 25 mg/m2 group. Hence, the MTD was determined as 20 mg/m2. At 3 months after corresponding treatment, the remission rate of nasopharyngeal tumors and neck-positive lymph nodes of the patients was 100%. The most common toxicity was reversible bone marrow suppression. \u0000 \u0000 \u0000Conclusions \u0000The MTD of weekly lobaplatin plus concurrent IMRT is 20 mg/m2 for locally advanced NPC. This regimen is reliable and safe, which is worthy of further clinical study. \u0000 \u0000 \u0000Key words: \u0000Nasopharyngeal neoplasm/concurrent chemoradiotherapy; Lobaplatin; Dose-limiting toxicity; Maximum tolerated dose","PeriodicalId":10288,"journal":{"name":"Chinese Journal of Radiation Oncology","volume":"29 1","pages":"171-174"},"PeriodicalIF":0.0,"publicationDate":"2020-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43278864","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Analysis of recurrence pattern of neoadjuvant therapy combined with surgical treatment for esophageal squamous cell carcinoma 食管鳞状细胞癌新辅助治疗联合手术治疗的复发模式分析
Pub Date : 2020-03-15 DOI: 10.3760/CMA.J.ISSN.1004-4221.2020.03.005
C. Fan, Zhu Feng, H. Ge, K. Ye, Hao Wang, Xiao-li Zheng, Yougai Zhang, Hui Luo
Objective To evaluate the recurrence pattern and identify the risk factors of esophageal squamous cell carcinoma after neoadjuvant therapy combined with surgery. Methods Clinical data of 275 patients with thoracic esophageal squamous cell carcinoma treated with neoadjuvant therapy combined with surgery from December 2011 to December 2015 were retrospectively analyzed. The follow-up data of the enrolled patients were complete and analyzable. The recurrence pattern, recurrence time, recurrence location and influencing factors after neoadjuvant therapy in combination with surgery were analyzed. The recurrence rate was calculated by Kaplan-Meier method. The multivariate analysis was performed by Cox regression model. Results The median follow-up time was 32(3-84) months, and the median time of the first recurrence was 10.6(2.0-69.1) months. The 1-, 2-and 3-year recurrence rates were 32.0%, 45.1% and 52.3%, respectively. A total of 152 cases (55.3%) had recurrence. Among them, 77 cases (50.6%) had local-regional recurrence (LRR), 34 cases (23.4%) had distant metastasis (DM), 33 cases (21.7%) had LRR+ DM and 8 cases (6.0%) had recurrence in unknown site. Among the patients with LRR, lymph node recurrence was the most common (n=98, 89.1%). For DM patients, lung metastasis (n=33, 49.3%), liver metastasis (n=16, 23.9%), bone metastasis (n=14, 20.9%) and non-regional lymph node metastasis (n=14, 20.9%) were commonly observed. The multivariate analysis showed that postoperative T stage (P=0.008), N stage (P<0.001) and the number of lymph node dissection (P<0.001) were the independent risk factors for recurrence after treatment. Conclusions The recurrence rate after neoadjuvant therapy remains relatively high for esophageal squamous cell carcinoma, and the regional lymph node is the most common site of recurrence. Postoperative pathological T staging, N staging and the number of lymph node dissection are the independent risk factors for recurrence after treatment. Key words: Esophageal neoplasm/neoadjuvant treatment; Recurrence pattern; Risk factor
目的探讨食管鳞状细胞癌术后新辅助治疗的复发模式及危险因素。方法回顾性分析2011年12月至2015年12月275例胸段食管鳞状细胞癌新辅助治疗联合手术治疗的临床资料。入选患者的随访数据是完整和可分析的。分析新辅助治疗结合手术后的复发模式、复发时间、复发部位及影响因素。复发率采用Kaplan-Meier法计算。采用Cox回归模型进行多元分析。结果中位随访时间为32(3-84)个月,中位首次复发时间为10.6(2.0-69.1)个月。1、2和3年复发率分别为32.0%、45.1%和52.3%。复发152例(55.3%)。其中77例(50.6%)局部复发,34例(23.4%)远处转移,33例(21.7%)LRR+DM,8例(6.0%)不明部位复发。在LRR患者中,淋巴结复发最为常见(n=98,89.1%)。DM患者中,肺转移(n=33,49.3%)、肝转移(n=16,23.9%)、骨转移(n=14,20.9%)和非区域淋巴结转移(n=14,209%)最为常见。多因素分析显示,术后T分期(P=0.008)、N分期(P<0.001)和淋巴结清扫次数(P<0.001。结论食管鳞状细胞癌新辅助治疗后复发率较高,局部淋巴结是最常见的复发部位。术后病理T分期、N分期和淋巴结清扫次数是治疗后复发的独立危险因素。关键词:食管肿瘤/新辅助治疗;复发模式;风险因素
{"title":"Analysis of recurrence pattern of neoadjuvant therapy combined with surgical treatment for esophageal squamous cell carcinoma","authors":"C. Fan, Zhu Feng, H. Ge, K. Ye, Hao Wang, Xiao-li Zheng, Yougai Zhang, Hui Luo","doi":"10.3760/CMA.J.ISSN.1004-4221.2020.03.005","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1004-4221.2020.03.005","url":null,"abstract":"Objective \u0000To evaluate the recurrence pattern and identify the risk factors of esophageal squamous cell carcinoma after neoadjuvant therapy combined with surgery. \u0000 \u0000 \u0000Methods \u0000Clinical data of 275 patients with thoracic esophageal squamous cell carcinoma treated with neoadjuvant therapy combined with surgery from December 2011 to December 2015 were retrospectively analyzed. The follow-up data of the enrolled patients were complete and analyzable. The recurrence pattern, recurrence time, recurrence location and influencing factors after neoadjuvant therapy in combination with surgery were analyzed. The recurrence rate was calculated by Kaplan-Meier method. The multivariate analysis was performed by Cox regression model. \u0000 \u0000 \u0000Results \u0000The median follow-up time was 32(3-84) months, and the median time of the first recurrence was 10.6(2.0-69.1) months. The 1-, 2-and 3-year recurrence rates were 32.0%, 45.1% and 52.3%, respectively. A total of 152 cases (55.3%) had recurrence. Among them, 77 cases (50.6%) had local-regional recurrence (LRR), 34 cases (23.4%) had distant metastasis (DM), 33 cases (21.7%) had LRR+ DM and 8 cases (6.0%) had recurrence in unknown site. Among the patients with LRR, lymph node recurrence was the most common (n=98, 89.1%). For DM patients, lung metastasis (n=33, 49.3%), liver metastasis (n=16, 23.9%), bone metastasis (n=14, 20.9%) and non-regional lymph node metastasis (n=14, 20.9%) were commonly observed. The multivariate analysis showed that postoperative T stage (P=0.008), N stage (P<0.001) and the number of lymph node dissection (P<0.001) were the independent risk factors for recurrence after treatment. \u0000 \u0000 \u0000Conclusions \u0000The recurrence rate after neoadjuvant therapy remains relatively high for esophageal squamous cell carcinoma, and the regional lymph node is the most common site of recurrence. Postoperative pathological T staging, N staging and the number of lymph node dissection are the independent risk factors for recurrence after treatment. \u0000 \u0000 \u0000Key words: \u0000Esophageal neoplasm/neoadjuvant treatment; Recurrence pattern; Risk factor","PeriodicalId":10288,"journal":{"name":"Chinese Journal of Radiation Oncology","volume":"29 1","pages":"179-183"},"PeriodicalIF":0.0,"publicationDate":"2020-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47251245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Partial research progress on precision hyperthermia for malignant tumors 恶性肿瘤精准热疗的部分研究进展
Pub Date : 2020-03-15 DOI: 10.3760/CMA.J.ISSN.1004-4221.2020.03.017
Jianing Qian, Zhi-bing Wu
Since the 21st century, with the changes of people′s living habits and the aggravation ofenvironmental pollution, the incidence of tumors has been increasing day by day, which has become the main deathcauseof human diseases. Atpresent, in addition to the three major conventional treatments of tumors, the emergence of hyperthermia provides a safer and more effective solution for the prevention and treatment of tumors. Attributed to the rapid development of mechanical manufacturing, computertechnology, molecularbiology, materials science and other disciplines, precision hyperthermia presented by radiofrequency and ultrasonic focusing hyperthermia guided by magnetic resonance imaging (MRI) non-invasive temperature measure technology, as well as molecular level targeted hyperthermia have provided a broader perspective for the treatment of tumors. This article reviews the partial research progress on precision hyperthermia to understand the current general situation of precision hyperthermia for tumors. Key words: Neoplasm/hyperthermia; Research progress
21世纪以来,随着人们生活习惯的改变和环境污染的加剧,肿瘤的发病率日益增加,已成为人类疾病的主要致死原因。目前,除了肿瘤的三大常规治疗方法外,热疗的出现为肿瘤的防治提供了更安全、更有效的解决方案。由于机械制造、计算机技术、分子生物学、材料科学等学科的快速发展,以磁共振成像(MRI)无创测温技术为指导的射频和超声聚焦热疗所呈现的精密热疗,以及分子水平的靶向热疗,为肿瘤的治疗提供了更广阔的前景。本文就精密热疗的部分研究进展进行综述,了解肿瘤精密热疗的现状。关键词:肿瘤/热疗;研究进展
{"title":"Partial research progress on precision hyperthermia for malignant tumors","authors":"Jianing Qian, Zhi-bing Wu","doi":"10.3760/CMA.J.ISSN.1004-4221.2020.03.017","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1004-4221.2020.03.017","url":null,"abstract":"Since the 21st century, with the changes of people′s living habits and the aggravation ofenvironmental pollution, the incidence of tumors has been increasing day by day, which has become the main deathcauseof human diseases. Atpresent, in addition to the three major conventional treatments of tumors, the emergence of hyperthermia provides a safer and more effective solution for the prevention and treatment of tumors. Attributed to the rapid development of mechanical manufacturing, computertechnology, molecularbiology, materials science and other disciplines, precision hyperthermia presented by radiofrequency and ultrasonic focusing hyperthermia guided by magnetic resonance imaging (MRI) non-invasive temperature measure technology, as well as molecular level targeted hyperthermia have provided a broader perspective for the treatment of tumors. This article reviews the partial research progress on precision hyperthermia to understand the current general situation of precision hyperthermia for tumors. \u0000 \u0000Key words: \u0000Neoplasm/hyperthermia; Research progress","PeriodicalId":10288,"journal":{"name":"Chinese Journal of Radiation Oncology","volume":"29 1","pages":"233-236"},"PeriodicalIF":0.0,"publicationDate":"2020-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44204825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of lncRNA MEG3 on radiosensitivity of nasopharyngeal carcinoma cells by down-regulating miR-7-5p expression lncRNA MEG3下调miR-7-5p表达对鼻咽癌细胞放射敏感性的影响
Pub Date : 2020-03-15 DOI: 10.3760/CMA.J.ISSN.1004-4221.2020.03.011
Xujuan Sun, Lifang Sun, M. Yu, Ying Li, Mingyan Li, Ke Yang, Yujie Li, G. Xing, Q. Han
Objective To investigate the effect and underlying mechanism of lncRNA MEG3 on the radiosensitivity of nasopharyngeal carcinoma cells. Methods this experiment, overexpression control group, MEG3 overexpression group, miR-NC inhibition group, miR-7-5p inhibition group, overexpression control+ 4 Gy group, MEG3 overexpression+ 4 Gygroup, miR-NC inhibition+ 4 Gy group, miR-7-5p inhibition+ 4 Gy group, MEG3 overexpression+ miR-NC overexpression group, MEG3 overexpression+ miR-7-5p overexpression group were established. The expression of miR-7-5p and MEG3 was detected by qRT-PCR. The radiosensitivity of nasopharyngeal carcinoma cells was measured by clone formation assay. Cell apoptosis was assessed by flow cytometry. The fluorescence activity was evaluated by dual luciferase reporter assay. Results MEG3 was lowly expressed in nasopharyngeal carcinoma tissues and cells. Overexpression of MEG3 and inhibition of miR-7-5p expression increased the radiosensitivity of nasopharyngeal carcinoma cells and promoted radiation-induced cell apoptosis. MEG3 could targetedly regulate the miR-7-5p expression. Overexpression of miR-7-5p reversed the effect of overexpression of MEG3 on the sensitization of nasopharyngeal carcinoma cells and the promotion of apoptosis induced by radiation exposure. Conclusions Overexpression of MEG3 increases the radiosensitivity of nasopharyngeal carcinoma cells and promotes radiation-induced cell apoptosis. The mechanism may be related to the down-regulation of miR-7-5p expression. Key words: lncRNA MEG3; miR-7-5p; Nasopharyngeal carcinoma cell line; Radiosensitivity; Apoptosis
目的探讨lncRNA MEG3对鼻咽癌细胞放射敏感性的影响及其机制。方法本实验设过表达对照组、MEG3过表达组、miR-NC抑制组、miR-7-5p抑制组、过表达控制+ 4gy组、MEG3过表达+ 4gy组、miR-NC抑制+ 4gy组、miR-7-5p抑制+ 4gy组、MEG3过表达+ miR-NC过表达组、MEG3过表达+ miR-7-5p过表达组。采用qRT-PCR检测miR-7-5p和MEG3的表达。用克隆形成法测定鼻咽癌细胞的放射敏感性。流式细胞术检测细胞凋亡情况。采用双荧光素酶报告基因法测定其荧光活性。结果MEG3在鼻咽癌组织和细胞中低表达。MEG3过表达和miR-7-5p表达抑制增加鼻咽癌细胞的放射敏感性,促进辐射诱导的细胞凋亡。MEG3可靶向调控miR-7-5p的表达。miR-7-5p过表达逆转了MEG3过表达对鼻咽癌细胞致敏和促进辐射暴露诱导的细胞凋亡的作用。结论MEG3过表达增加鼻咽癌细胞的放射敏感性,促进辐射诱导的细胞凋亡。其机制可能与miR-7-5p表达下调有关。关键词:lncRNA MEG3;miR-7-5p;鼻咽癌细胞系;辐射敏感度;细胞凋亡
{"title":"Effect of lncRNA MEG3 on radiosensitivity of nasopharyngeal carcinoma cells by down-regulating miR-7-5p expression","authors":"Xujuan Sun, Lifang Sun, M. Yu, Ying Li, Mingyan Li, Ke Yang, Yujie Li, G. Xing, Q. Han","doi":"10.3760/CMA.J.ISSN.1004-4221.2020.03.011","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1004-4221.2020.03.011","url":null,"abstract":"Objective \u0000To investigate the effect and underlying mechanism of lncRNA MEG3 on the radiosensitivity of nasopharyngeal carcinoma cells. \u0000 \u0000 \u0000Methods \u0000this experiment, overexpression control group, MEG3 overexpression group, miR-NC inhibition group, miR-7-5p inhibition group, overexpression control+ 4 Gy group, MEG3 overexpression+ 4 Gygroup, miR-NC inhibition+ 4 Gy group, miR-7-5p inhibition+ 4 Gy group, MEG3 overexpression+ miR-NC overexpression group, MEG3 overexpression+ miR-7-5p overexpression group were established. The expression of miR-7-5p and MEG3 was detected by qRT-PCR. The radiosensitivity of nasopharyngeal carcinoma cells was measured by clone formation assay. Cell apoptosis was assessed by flow cytometry. The fluorescence activity was evaluated by dual luciferase reporter assay. \u0000 \u0000 \u0000Results \u0000MEG3 was lowly expressed in nasopharyngeal carcinoma tissues and cells. Overexpression of MEG3 and inhibition of miR-7-5p expression increased the radiosensitivity of nasopharyngeal carcinoma cells and promoted radiation-induced cell apoptosis. MEG3 could targetedly regulate the miR-7-5p expression. Overexpression of miR-7-5p reversed the effect of overexpression of MEG3 on the sensitization of nasopharyngeal carcinoma cells and the promotion of apoptosis induced by radiation exposure. \u0000 \u0000 \u0000Conclusions \u0000Overexpression of MEG3 increases the radiosensitivity of nasopharyngeal carcinoma cells and promotes radiation-induced cell apoptosis. The mechanism may be related to the down-regulation of miR-7-5p expression. \u0000 \u0000 \u0000Key words: \u0000lncRNA MEG3; miR-7-5p; Nasopharyngeal carcinoma cell line; Radiosensitivity; Apoptosis","PeriodicalId":10288,"journal":{"name":"Chinese Journal of Radiation Oncology","volume":"29 1","pages":"207-210"},"PeriodicalIF":0.0,"publicationDate":"2020-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46671389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Study of the feasibility of needle path optimization in 3D brachytherapy for cervical cancer 宫颈癌三维近距离放射治疗中针路优化可行性研究
Pub Date : 2020-03-15 DOI: 10.3760/CMA.J.ISSN.1004-4221.2020.03.013
Xiang Chen, Jianliang Zhou, Xiang-hua Zhang, Binbing Wang
Objective To compare the dosimetric differences between free-hand method and virtually optimized method for implanting needles in intracavitary and interstitial combined brachytherapy (IC/IS BT) of cervical cancer, and to explore the improvement space of the existing interstitial brahcytherapy plan. Methods High-dose-rate cervical cancer IC/IS BT plans (short for Treatment-Plan) of 18 cases were retrospectively analyzed. For each treatment plan, Nucletron Oncentra 3D brachytherapy planning system was utilized to redesign the virtually optimized insertion method IC/IS BT plan (short for Optimized-Plan). Dose volume histogram was adopted to evaluate the dose distribution in high-risk clinical target areas and exposure dose to organ at risk (OAR). The plan execution efficiency between two plans was also assessed. Results Comparing these two plans, the differences in conformity and uniformity of dose distribution of the target area were statistically significant (P=0.000, 0.008). The differences of D0.01 cm3, D1 cm3, D2 cm3 and D5 cm3 in bladder, rectum, sigmoid and small bowel were all statistically significant (all P<0.05). Optimized-Plan could reduce the D2 cm3 of bladder, rectum, sigmoid and small bowel by 60.41, 36.43, 27.53 and 12.43 cGy, respectively. The execution time for the Treatment-Plan and Optimized-Plan were (857.92±243.39) s and (804.53±239.13) s with statistical significance (P<0.001). Conclusions Compared with the free-hand method, virtually optimized method yields more conformable coverage of the target area and more uniform dose distribution. At the same time, the doses of each OAR are reduced to different degrees and the execution time of the plan is also shortened. Key words: Cervical neoplasm/brachytherapy; Interstitial implant; Intracavitary irradiation
目的比较癌症腔内和间质联合近距离放射治疗(IC/IS-BT)中自由手法与虚拟优化法的剂量差异,探讨现有间质内放疗方案的改进空间。方法回顾性分析18例癌症高部位IC/IS BT方案(简称治疗方案)的临床资料。对于每个治疗计划,Nucletron Oncentra 3D近距离放射治疗计划系统被用于重新设计虚拟优化的插入方法IC/IS BT计划(优化计划的缩写)。采用剂量-体积直方图评估高危临床靶区的剂量分布和对危险器官的暴露剂量(OAR)。还评估了两个计划之间的计划执行效率。结果比较两种方案,靶区剂量分布的一致性和均匀性差异有统计学意义(P=0.000,0.008)。膀胱、直肠、乙状结肠和小肠D0.01 cm3、D1 cm3、D2 cm3和D5 cm3的差异均有统计学意义(均P<0.05),乙状结肠和小肠分别增加60.41、36.43、27.53和12.43cGy。治疗方案和优化方案的执行时间分别为(857.92±243.39)s和(804.53±239.13)s,具有统计学意义(P<0.001)。同时,每个OAR的剂量都不同程度地减少,计划的执行时间也缩短了。关键词:宫颈肿瘤/近距离放射治疗;间质植入物;腔内照射
{"title":"Study of the feasibility of needle path optimization in 3D brachytherapy for cervical cancer","authors":"Xiang Chen, Jianliang Zhou, Xiang-hua Zhang, Binbing Wang","doi":"10.3760/CMA.J.ISSN.1004-4221.2020.03.013","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1004-4221.2020.03.013","url":null,"abstract":"Objective \u0000To compare the dosimetric differences between free-hand method and virtually optimized method for implanting needles in intracavitary and interstitial combined brachytherapy (IC/IS BT) of cervical cancer, and to explore the improvement space of the existing interstitial brahcytherapy plan. \u0000 \u0000 \u0000Methods \u0000High-dose-rate cervical cancer IC/IS BT plans (short for Treatment-Plan) of 18 cases were retrospectively analyzed. For each treatment plan, Nucletron Oncentra 3D brachytherapy planning system was utilized to redesign the virtually optimized insertion method IC/IS BT plan (short for Optimized-Plan). Dose volume histogram was adopted to evaluate the dose distribution in high-risk clinical target areas and exposure dose to organ at risk (OAR). The plan execution efficiency between two plans was also assessed. \u0000 \u0000 \u0000Results \u0000Comparing these two plans, the differences in conformity and uniformity of dose distribution of the target area were statistically significant (P=0.000, 0.008). The differences of D0.01 cm3, D1 cm3, D2 cm3 and D5 cm3 in bladder, rectum, sigmoid and small bowel were all statistically significant (all P<0.05). Optimized-Plan could reduce the D2 cm3 of bladder, rectum, sigmoid and small bowel by 60.41, 36.43, 27.53 and 12.43 cGy, respectively. The execution time for the Treatment-Plan and Optimized-Plan were (857.92±243.39) s and (804.53±239.13) s with statistical significance (P<0.001). \u0000 \u0000 \u0000Conclusions \u0000Compared with the free-hand method, virtually optimized method yields more conformable coverage of the target area and more uniform dose distribution. At the same time, the doses of each OAR are reduced to different degrees and the execution time of the plan is also shortened. \u0000 \u0000 \u0000Key words: \u0000Cervical neoplasm/brachytherapy; Interstitial implant; Intracavitary irradiation","PeriodicalId":10288,"journal":{"name":"Chinese Journal of Radiation Oncology","volume":"29 1","pages":"215-219"},"PeriodicalIF":0.0,"publicationDate":"2020-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43008388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Daily quality control data analysis and process evaluation of linear accelerator 直线加速器日常质量控制数据分析及工艺评价
Pub Date : 2020-03-15 DOI: 10.3760/CMA.J.ISSN.1004-4221.2020.03.014
Xiaoli Jin, Ying Lu, Qinying Shi, Lin Hao, Xiaofen Xing
Objective To analyze the quality control data of linear accelerator detected by Daily QA3 and to evaluate this quality control process using statistical process control. Methods After the calibrations of the accelerator and Daily QA3, Daily QA3 device was used to perform daily quality control by technicians and physicists and 100 groups and 30 groups of daily quality control data were collected. After the accelerator and Daily QA3 were re-calibrated, Daily QA3 device was utilized to perform daily quality control by technicians and 100 groups of the daily quality control data were repeatedly collected. The variations of normalized signal-to-noise ratio of quality control data collected after two calibrations were analyzed. The first 30 groups of daily quality control data measured by technicians and physicists were adopted to calculate the I-MR control chartsand compare the location of CL and the range of UCL and LCL. The process capability indices were calculated for three different quality control processes bytechnicians and physicists, respectively. Results For twice calibrations, normalized signal-to-noise ratio of quality control data significantly changed before 6 weeks, became stable between 6 and 8 weeks, and the changes became smaller after 8 weeks. For dose output measured by physicists, the rang of UCL and LCL was more narrow. In terms of flatness and symmetry, the location of CL was closer to zero. Regarding dose output and flatness, the process capability indices of three different quality control process were all satisfied ≥1, whereas unsatisfied for transverse symmetry. Conclusions The first 30-40 data points should be adopted to delineate I-MR control chart of the linear accelerator in daily quality control process. The quality control process should be completed by a fixed and small group of personnel and an optimal tolerance level should be customized. Key words: Linear accelerator; Quality control; Statistical process control; Control chart; Process capability index
目的分析Daily QA3检测直线加速器的质量控制数据,并应用统计过程控制方法对直线加速器的质量控制过程进行评价。方法在对加速器和Daily QA3进行标定后,由技术人员和物理学家利用Daily QA3装置进行日常质控,收集100组和30组日常质控数据。加速器和Daily QA3重新校准后,由技术人员利用Daily QA3装置进行日常质控,重复采集100组日常质控数据。分析了两次标定后质控数据归一化信噪比的变化规律。采用技术人员和物理学家测量的前30组日常质量控制数据计算I-MR控制图,并比较CL的位置以及UCL和LCL的范围。分别由技术人员和物理人员计算了三种不同质量控制过程的过程能力指标。结果两次校准后,质控数据的归一化信噪比在6周前有显著变化,在6 ~ 8周间趋于稳定,8周后变化变小。对于物理学家测量的剂量输出,UCL和LCL的范围较窄。在平整度和对称性方面,CL的位置更接近于零。在剂量输出和平整度方面,3种不同质量控制工艺的工艺能力指标均满足≥1,而横向对称性不满足。结论在日常质量控制过程中,应采用前30-40个数据点划定直线加速器的I-MR控制图。质量控制过程应由固定的小团队人员完成,并应定制最佳公差水平。关键词:直线加速器;质量控制;统计过程控制;控制图;过程能力指数
{"title":"Daily quality control data analysis and process evaluation of linear accelerator","authors":"Xiaoli Jin, Ying Lu, Qinying Shi, Lin Hao, Xiaofen Xing","doi":"10.3760/CMA.J.ISSN.1004-4221.2020.03.014","DOIUrl":"https://doi.org/10.3760/CMA.J.ISSN.1004-4221.2020.03.014","url":null,"abstract":"Objective \u0000To analyze the quality control data of linear accelerator detected by Daily QA3 and to evaluate this quality control process using statistical process control. \u0000 \u0000 \u0000Methods \u0000After the calibrations of the accelerator and Daily QA3, Daily QA3 device was used to perform daily quality control by technicians and physicists and 100 groups and 30 groups of daily quality control data were collected. After the accelerator and Daily QA3 were re-calibrated, Daily QA3 device was utilized to perform daily quality control by technicians and 100 groups of the daily quality control data were repeatedly collected. The variations of normalized signal-to-noise ratio of quality control data collected after two calibrations were analyzed. The first 30 groups of daily quality control data measured by technicians and physicists were adopted to calculate the I-MR control chartsand compare the location of CL and the range of UCL and LCL. The process capability indices were calculated for three different quality control processes bytechnicians and physicists, respectively. \u0000 \u0000 \u0000Results \u0000For twice calibrations, normalized signal-to-noise ratio of quality control data significantly changed before 6 weeks, became stable between 6 and 8 weeks, and the changes became smaller after 8 weeks. For dose output measured by physicists, the rang of UCL and LCL was more narrow. In terms of flatness and symmetry, the location of CL was closer to zero. Regarding dose output and flatness, the process capability indices of three different quality control process were all satisfied ≥1, whereas unsatisfied for transverse symmetry. \u0000 \u0000 \u0000Conclusions \u0000The first 30-40 data points should be adopted to delineate I-MR control chart of the linear accelerator in daily quality control process. The quality control process should be completed by a fixed and small group of personnel and an optimal tolerance level should be customized. \u0000 \u0000 \u0000Key words: \u0000Linear accelerator; Quality control; Statistical process control; Control chart; Process capability index","PeriodicalId":10288,"journal":{"name":"Chinese Journal of Radiation Oncology","volume":"29 1","pages":"220-224"},"PeriodicalIF":0.0,"publicationDate":"2020-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44873949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
中华放射肿瘤学杂志
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1